Home > Haematology > EHA 2021 > Thrombotic and Thrombocytopenic Disorders including COVID-19 related > Acquired TTP: new treatments and updated guidelines

Acquired TTP: new treatments and updated guidelines

Presented By
Dr María Mingot-Castellano, Hospital Universitario Virgen del Rocío, Spain
EHA 2021
New, effective treatments have become available for patients with acquired thrombotic thrombocytopenia (aTTP). Updated guidelines include new treatment decision trees and recommendations for the monitoring of patients in remission. Dr María Mingot-Castellano (Hospital Universitario Virgen del Rocío, Spain) reviewed some significant changes in aTTP management in the last 5 years as a result of the introduction of new drugs, guidelines, and real-world data [1]. The evolution of therapeutic strategies started in 1975 with the introduction of corticosteroids and plasma exchange, which increased survival from 10% to 78% [2]. However, ≤42% of patients are refractory to plasma exchange and immunosuppression and the risk of relapse is 30–50%. Today, treatment strategies aim to stop inhibitor production, supply ADAMTS13 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif) and prevent thrombus formation. To stop inhibitor product...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on